Fenebrutinib's FDA Priority Review: First-in-Class BTK Inhibitor in MS Faces Binary Safety Adjudication

FDA Accepts Roche's Fenebrutinib for MS Priority Review

The FDA has accepted Roche's application for its experimental multiple sclerosis pill, fenebrutinib, initiating a priority review with a six-month timeline. This positions fenebrutinib to potentially be the first BTK inhibitor approved for both relapsed and primary progressive forms of MS. The application is supported by three late-stage studies that met their main objectives. However, the review faces complications due to an observed imbalance in deaths among fenebrutinib recipients (8 vs 1 in comparator) and pre-existing regulatory concerns about liver safety, including one case meeting "Hy’s law" criteria. Roche maintains the deaths had various causes and the drug's safety profile is manageable across its development program, which includes a large safety database of over 2,700 participants.

• FDA Grants Priority Review for Fenebrutinib in MS: The FDA has accepted Roche's application for fenebrutinib, granting it a priority review with a six-month timeline. This decision could lead to fenebrutinib becoming the first BTK inhibitor approved for both relapsed and primary progressive multiple sclerosis, based on positive outcomes from a trio of late-stage studies. This marks a significant step for Roche in addressing a complex autoimmune disorder where other BTK inhibitors have faced challenges.
• Significant Safety Concerns Identified During Review: Despite meeting primary objectives, fenebrutinib's approval path is complicated by safety concerns. These include an imbalance in deaths, with eight fatalities among fenebrutinib recipients across two Phase 3 studies compared to one in the comparator arm (Aubagio). Additionally, a case of liver enzyme elevations meeting "Hy’s law" criteria was reported, alongside pre-existing regulatory concerns about the liver safety profile of BTK inhibitors, which previously led to a partial clinical hold.
• Roche Asserts Manageable Safety Profile with Extensive Data: Roche has addressed the safety concerns, stating that the observed deaths "occurred at different timepoints and had various causes." The company asserts that fenebrutinib's overall safety profile is "manageable" throughout its extensive development program. This claim is supported by a large safety database encompassing more than 2,700 study participants, suggesting a comprehensive understanding of the drug's risk-benefit profile.

Fenebrutinib's Potential to Reshape the MS Treatment Landscape

Over the past five years, the multiple sclerosis treatment landscape has been shaped by a growing recognition that currently available disease-modifying therapies (DMTs) — while effective at reducing peripheral immune activity and relapse rates — have limited impact on CNS-compartmentalized inflammation, a key driver of disability progression. This has prompted intensive investigation into therapies capable of crossing the blood-brain barrier. Bruton's tyrosine kinase inhibitors (BTKIs) have emerged as a leading next-generation approach, targeting both B cells and microglia within the CNS. Evobrutinib, tolebrutinib, and fenebrutinib have each demonstrated efficacy and safety in relapsing MS in phase 2 studies, with evobrutinib and tolebrutinib showing sustained results in extension studies of up to 3–5 years. However, evobrutinib failed to distinguish itself from teriflunomide on the primary endpoint of relapse rate reduction in two phase 3 studies, underscoring that phase 2 promise does not always translate to phase 3 success and that differentiation between individual BTKIs remains an open question pending further trial readouts.

Alongside the BTKI pipeline, established high-efficacy therapies have been evaluated in previously understudied populations and settings. In early-stage relapsing-remitting MS, the phase IIIb ENSEMBLE study demonstrated that ocrelizumab, administered as a first-line therapy in treatment-naive patients over 192 weeks, achieved NEDA-3 in 66.4% of patients, with an adjusted annualised relapse rate of 0.020 and no new safety signals. In patients over 60, real-world data from the MSBase registry showed that ocrelizumab reduced the IPTW-weighted ARR to 0.01 versus 0.08 for interferon/glatiramer acetate, with an ARR ratio of 0.15 (95% CI 0.06–0.33, p<0.001), though no significant difference in confirmed disability progression or improvement was observed over 3.57 years. Similarly, in late-onset MS, moderate-high-efficacy DMTs reduced the annualised relapse rate with an ARR ratio of 0.68 (95% CI 0.50–0.93, p=0.01) compared to low-efficacy DMTs, though effects on confirmed disability progression did not reach statistical significance.

A broader network meta-analysis of 33 randomised controlled trials evaluating 16 DMTs confirmed that several agents — including ponesimod (ROM = 0.52), ofatumumab (ROM = 0.58), alemtuzumab (ROM = 0.63), and natalizumab (ROM = 0.77) — significantly reduce brain volume loss compared to placebo, with treatment effects on brain volume loss independently associated with reduced disability accumulation (β = 0.422; p = 0.005 after adjusting for MRI lesion activity). Real-world comparative data from the MENACTRIMS registry further indicated that natalizumab was associated with a lower ARR than anti-CD20 therapies (0.062 vs. 0.092, p=0.001) and higher rates of disability improvement (9.3% vs. 5.5%, p=0.03), though adverse events were more frequent in the anti-CD20 group (36.4% vs. 27.5%, p=0.001). Collectively, these findings reflect a treatment landscape increasingly oriented toward earlier, higher-efficacy intervention, CNS-penetrant mechanisms, and more granular characterisation of benefit-risk profiles across distinct patient subgroups.

Fenebrutinib's Efficacy and Navigating Persistent Safety Concerns

Across its studied indications — multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and chronic spontaneous urticaria — fenebrutinib has demonstrated a broadly acceptable safety profile, though with indication-specific nuances. In the Phase II SLE trial, safety results were similar across the placebo, fenebrutinib 150 mg once daily, and fenebrutinib 200 mg twice daily arms, although serious adverse events were more frequent with the 200 mg twice daily dose. In the Phase II ANDES study in rheumatoid arthritis, the most common adverse events included nausea, headache, anemia, and upper respiratory tract infections, with the overall safety profile described as consistent with existing immunomodulatory therapies for RA.

Hepatotoxicity represents the most clinically significant safety signal for fenebrutinib and the BTK inhibitor class more broadly. In a systematic review and meta-analysis of six RCTs encompassing 3,616 participants across MS phenotypes, serious hepatotoxicity was reported in 11.0% of BTKi-treated patients compared with 13.7% of control patients (pooled RR 0.80; 95% CI 0.66–0.96). However, increased transaminase elevations were reported in placebo-controlled trials, indicating that hepatotoxicity remains a clinically relevant safety concern for the class. Consistent with this, a 2026 review of BTK inhibitors in MS noted that adverse events include elevated liver enzymes, which can reach life-threatening levels, underscoring the need for continued hepatic monitoring in clinical practice.

From a cardiac safety standpoint, a dedicated Phase I QT/QTc study in healthy participants found that both therapeutic (400 mg) and supratherapeutic (700 mg) single doses of fenebrutinib had no clinically meaningful impact on the QT interval. In Part B of that study (n = 85), all upper bounds of one-sided 95% confidence intervals for the least squares mean placebo-adjusted ΔΔQTcF values were < 10 ms, with maximum observed values of 5.3 ms and 8.2 ms at 1 hour after the therapeutic and supratherapeutic doses, respectively. No serious adverse events, adverse events of special interest, or Grade ≥ 2 adverse events were observed in Part A (n = 16), supporting fenebrutinib's favorable cardiac safety profile and its continued clinical development.

The Challenging Landscape of BTK Inhibitors in MS

Fenebrutinib is a BTK inhibitor under investigation for multiple sclerosis, sharing its mechanism of action with several other agents in active clinical development. The BTK inhibitor class targets both peripheral B cells and CNS-resident myeloid cells, distinguishing it from conventional high-efficacy DMTs that primarily suppress relapse activity.

The knowledge base does not have sufficient information on this aspect.

Fenebrutinib's Dual MS Promise Faces Critical Safety Review

The FDA's decision to grant priority review to Roche's fenebrutinib for multiple sclerosis signals a critical juncture for both the company and the broader MS treatment paradigm. Fenebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, holds the promise of being the first oral therapy approved for both relapsing and primary progressive forms of MS. This is particularly significant given the substantial unmet need in progressive MS, where existing therapies often fall short due to their inability to effectively cross the blood-brain barrier and modulate the CNS-compartmentalized inflammation driven by microglia and macrophages.

The scientific rationale for BTK inhibition in MS is robust, targeting key immune cells involved in both adaptive and innate immunity. Studies indicate that BTK is upregulated in active and chronic active MS lesions, supporting the use of brain-penetrant BTK inhibitors. If approved, fenebrutinib could offer a novel approach to disease modification, potentially slowing disability progression in a patient population with limited options. This would not only differentiate fenebrutinib within the evolving BTK inhibitor class but also solidify Roche's position in the competitive neurology market.

However, the path to approval is not without significant challenges. The observed imbalance in deaths among fenebrutinib recipients, coupled with pre-existing regulatory concerns about liver safety, including a 'Hy’s law' case, introduces considerable risk. While Roche maintains the deaths had various causes and points to a large safety database, these issues will undoubtedly be under intense scrutiny during the priority review. Hepatotoxicity is a known class-wide concern for BTK inhibitors, and any further safety signals could lead to a more restrictive label, stringent monitoring requirements, or even a delay in approval. The outcome of this review will therefore be a crucial indicator of the balance between the potential for broad efficacy in MS and the imperative for a robust safety profile, shaping the future landscape of MS management.